Drawing for BRAFCOVI

USPTO serial 87274926

BRAFCOVI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HELFMAN, JUDITH MICHELLE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BRAFCOVI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Cynthia Johnson Walden

CYNTHIA JOHNSON WALDEN FISH & RICHARDSON P.C.P. O. BOX 1022MINNEAPOLIS, MN 55440-1022UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer and tumors; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 2, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 2, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 10, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 8, 2019EX4GSOU EXTENSION 4 GRANTED—
Jul 8, 2019EXT4SOU EXTENSION 4 FILED—
Jul 8, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 16, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2019EX3GSOU EXTENSION 3 GRANTED—
Jan 14, 2019EXT3SOU EXTENSION 3 FILED—
Jan 14, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 12, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 10, 2018EX2GSOU EXTENSION 2 GRANTED—
Jul 10, 2018EXT2SOU EXTENSION 2 FILED—
Jul 10, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 10, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 8, 2018EX1GSOU EXTENSION 1 GRANTED—
Jan 8, 2018EXT1SOU EXTENSION 1 FILED—
Jan 8, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 25, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 30, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 30, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 10, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 21, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Mar 21, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 21, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 21, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 21, 2017ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Mar 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 21, 2017DOCKASSIGNED TO EXAMINER—
Dec 29, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 23, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance